Cytotoxic ribonuclease variants

Details Cytotoxic ribonuclease variants Cytotoxic ribonuclease variants

2009-07-02

2011-11-01

Aeder, Sean (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

Reexamination Certificate

active

08048425

ABSTRACT:
This invention relates to cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined by the three dimensional (3-D) atomic structure of the RNase1 hRI complex. Also disclosed is the 3-D structure of the hRI•RNase 1 complex and methods for designing the RNase 1 variants.

REFERENCES:
patent: 5840296 (1998-11-01), Raines et al.
patent: 6280991 (2001-08-01), Raines et al.
patent: 7416875 (2008-08-01), Raines et al.
patent: 7655757 (2010-02-01), Raines et al.
patent: 2005/0261232 (2005-11-01), Strong et al.
patent: 2006/0292137 (2006-12-01), Raines et al.
patent: 2009/0311784 (2009-12-01), Raines et al.
patent: 778024 (2005-03-01), None
patent: 2002301972 (2006-03-01), None
patent: 2306442 (2010-04-01), None
patent: 1896579 (2008-03-01), None
patent: 1023447 (2008-08-01), None
patent: 1910541 (2010-10-01), None
patent: 143036 (2009-09-01), None
patent: 200817144 (2008-05-01), None
patent: 2008517102 (2008-05-01), None
patent: 9919494 (1994-04-01), None
patent: 0031242 (2000-03-01), None
patent: 0040608 (2000-07-01), None
patent: 2006138458 (2006-12-01), None
Burgess et al. (J. Cell Biol. 111:2129-2138, 1990).
Lazar et al. ( Mol. Cell Biol. 8:1247-1252, 1998).
Newton et al (The Journal of Neuroscience, 1994, 14(2): 538-544).
Boix, E., et al, “Role of the N Terminus in RNase A Homologues: Differences in Catalytic Activity, Ribonuclease Inhibitor Interaction and Cytotoxicity,” J. Mol. Biol. 257:992-1007 (1996).
Bosch, M. et al., “A Nuclear Localization Sequence Endows Human Pancreatic Ribonuclease With Cytotoxic Activity,” Biochemistry 43:2167-2177 (2004).
Gaur, D., et al., “Interaction of Human Pancreatic Ribonuclease with Human Ribonuclease Inhibitor,” The Journal of Biological Chemistry 276:24978-24984(2001).
Kobe, B., et al., “A structural basis of the interactions between leucine-rich repeats and protein ligands,” Nature 374-:183-186 (1995).
Kobe, G. et al., “Mechanism of Ribonuclease Inhibition by Ribonuclease Inhibitor Protein Based on the crystal Structure of its Complex with Ribonuclease A.” J. Mol. Biol. 264:1028-1043 (1996).
Kumar, K. et al., “Selective abolition of pancreatic RNase binding to its inhibitor protein,” PNAS 101:53-58 (2004).
Lee, J.E., et al., “Cytotoxicity of Bovine Seminal Ribonuclease: Monomer versus Dimer,” Biochemistry 44:15760-15767 (2005).
Leland, P.A.,et al., “Ribonuclease A variants with potent cytotoxic activity,” Proc. Natl. Acad. Sci. USA 95:10407-10412 (1998).
Leland, P.A. et al., Endowing Human Pancreatic Ribonuclease with Toxicity for Cancer Cells, The Journal of Biological Chemistry 276:43095-43102 (2001).
Mitchell, J.C., et al., “Rapid atomic density methods for molecular shape characterization,” Journal of Molecular Graphics and Modeling 19:325-330 (2001).
Pous, J., et al., “Three-dimensional Structure of a Human Pancreatic Ribonuclease Varient, a Step Forward in the Design of Cytotoxic Ribonucleases,” J. Mol. Biol. 303:49-59 (2000).
Pous, J., et al., “Three-dimensional Structure of Human RNase 1 delta N7 at 1.9 a resolution,” Acta Cryst. D57:498-505 (2001).
Rajamani, D., et al., “Anchor residues in protein-protein interactions,” PNAS 101:11287-11292 (2004).
Rutkoski, T.J., et al., “Disruption of Shape-Complementarity Markers to Create Cytotoxic Varients of Ribonuclease A,” J. Mol. Biol. 354:41-54 (2005).
Shaul, Y., et al., “Exploring the Charge Space of Protein-Protien Association: A Proteomic Study,” Proteins: Structure, Function, and Bioinformatics 60:331-352 (2005).
Gura (Science,1997, 278:1041-1042).
Murphy, B.S., et al., “Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor,” Biochem, J. 281:343-348 (1992).
Rutkoski, T.J., et al., “Disruption of Shape-Complementarity Markers to Create Cytotoxic Variants of Ribonuclease A.” J. Mol. Biol. 354:41-54 (2005).
Quintessence/Biosciences webpage on Evade TM Ribonucleases, (2009).
Burgess, et al., (J. Cell Biol. 111:2129-2138, 1990).
Lazar, et al., (Mol. Cell Biol. 8:1247-1252, 1998).
Ontjes, et al., (PNAS, Oct. 1969, 64(2): 428-35).
International Search Report dated Nov. 13, 2006 (International Patent Application No. PCT/US2006/023298; filed on Jun. 16, 2006).
Written Opinion dated Dec. 16, 2007 (International Patent Application No. PCT/US2006/023298; filed on Jun. 16, 2006).
International Preliminary Report on Patentability dated Dec. 17, 2007 (International Patent Application No. PCT/US2006/023298; filed on Jun. 16, 2006).
International Search Report dated Aug. 2, 2007 (International Patent Application No. PCT/US2006/023485; filed on Jun. 16, 2006).
Written Opinion dated Dec. 16, 2007 (International Patent Application No. PCT/US2006/023485; filed on Jun. 16, 2006).
International Preliminary Report on Patentability dated Dec. 17, 2007 (International Patent Application No. PCT/US2006/023485; filed on Jun. 16, 2006).
International Search Report dated Nov. 23, 2000 (International Patent Application No. PCT/US19927670; filed on Nov. 22, 1999).
Notice of Allowance dated Apr. 17, 2008 (U.S. Appl. No. 11/454,379, filed Jun. 16, 2006).
Non-Final Rejection dated Aug. 9, 2007 (U.S. Appl. No. 11/454,379, filed Jun. 16, 2006).
Non-Final Rejection dated May 16, 2006 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Non-Final Rejection dated Sep. 5, 2007 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Non-Final Rejection dated Mar. 9, 2007 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Final Rejection dated Oct. 31, 2008 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Advisory Action dated Jan. 13, 2009 (U.S. Appl. No. 11/454,418, filed Jun. 16, 2006).
Murphy et al., “Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor”, Biochem. J. Mol. Biol. 354:41-54 (2005).
Quintessence/Biosciences webpages on Evade TM Ribonucleases, May 9, 2011.
Communication under Rule 71 (3) EPC (European Patent Application No. 98951054.0-2401, filed Oct. 13, 1998).
Examination Report dated May 14, 2003 (European Patent Application No. 98951054.0-2401, filed Oct. 13, 1998).
Examination Report dated Mar. 9, 2004 (European Patent Application No. 98951054.0-2401, filed Oct. 13, 1998).
Examination Report dated Apr. 27, 2005 (European Patent Application No. 98951054.0-2401, filed Oct. 13, 1998).
Notice of Allowance dated Sep. 29, 2009 (Canadian Patent Application No. 2306442, filed Oct. 13, 1998).
Office Action dated Dec. 4, 2007 (Canadian Patent Application No. 2306442, filed Oct. 13, 1998).
Office Action dated Oct. 20, 2006 (Canadian Patent Application No. 2306442, filed Oct. 13, 1998).
Examiner's Report dated Nov. 17, 2004 (Australian Patent Application No. 2002301972, filed Nov. 13, 2006).
Examiner's Report dated Aug. 10, 2005 (Australian Patent Application No. 2002301972, filed Nov. 13, 2006).
Notice of Acceptance dated Nov. 22, 2005 (Australian Patent Application No. 2002301972, filed Nov. 13, 2006).
Kim et al., Structural Basis for the Biological Activities of Bovine Seminal Ribonuclease, J. Biol. Chem. 270, No. 18: 10 525-1 0530, 1995.
Murthy et al., Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor (Biochem. J., 1992, 281:343-348).
Schein, From Housekeeper to Microsurgeon: The Diagnostic and Therapeutic Potential of Ribonucleases, Nature Biotechnology 15:529-536, 1997.
Non-Final Rejection dated Feb. 9, 2011 (U.S. Appl No. 12/497,038, filed Jul. 2, 2009).
Requirement for Restriction/Election dated Oct. 5, 2010 (U.S. Appl No. 12/497,038, filed Jul. 2, 2009).
Communication under Rule 71(3) EPC dated May 4, 2010 (Appl. No. 06784926.5, filed Jun. 16, 2006).
Examination Report dated Aug. 19, 2009 (EP Patent Application No. 06784995.0-2401, filed Jun. 16, 2006).
Examination Report dated Nov

Affiliated with

Also associated with

Rating

Cytotoxic ribonuclease variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytotoxic ribonuclease variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic ribonuclease variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4312607